ACTIVE_NOT_RECRUITING

Neurofeedback to Improve Working Memory in Mild Cognitive Impairment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Mild cognitive impairment (MCI) has been identified as an early phase of Alzheimer's disease (AD), a neurodegenerative disorder expected to affect 13.9 million Americans by 2060. AD causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality. Treatment intervention at the MCI stage of the disease could potentially slow down the rate at which people may convert from MCI to AD. Increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in AD. Furthermore, previous research has shown that neurofeedback (NFB) training targeting these regions can improve memory, making it a potential treatment for AD. NFB is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor. We are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with MCI. Results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with MCI.

Official Title

Enhancing Gamma Band Response in Mild Cognitive Impairment to Improve Working Memory

Quick Facts

Study Start:2021-01-01
Study Completion:2026-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT04566900

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Meet criteria for mild cognitive impairment (MCI).
  2. 2. Living independently.
  3. 3. Literate in English.
  4. 4. Competent to participate in the informed consent process and provide voluntary informed consent.
  1. 1. Frontal temporal dementia
  2. 2. Active alcohol or substance use disorder within the past year.
  3. 3. Brain cancer
  4. 4. Stroke within the last 2 years
  5. 5. Anti-epileptic medication
  6. 6. Prior head injury involving loss of consciousness
  7. 7. Seizure disorder
  8. 8. Use of medications likely to affect cognitive function (cf. donepezil, memantine). We will not exclude for other medications but will examine their effects and include medications as covariates as appropriate (e.g., presence v. absence; anticholinergic load).
  9. 9. The potential benefits of the study do not outweigh the potential risks of the study, as determined by the PI.

Contacts and Locations

Study Locations (Sites)

University of California at San Diego
La Jolla, California, 92093
United States

Collaborators and Investigators

Sponsor: University of California, San Diego

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-01-01
Study Completion Date2026-08-31

Study Record Updates

Study Start Date2021-01-01
Study Completion Date2026-08-31

Terms related to this study

Keywords Provided by Researchers

  • neurofeedback

Additional Relevant MeSH Terms

  • Mild Cognitive Impairment